Placebo matched to ocrelizumab

Phase 3Monoclonal antibody

Placebo matched to ocrelizumab is one of 3 therapeutic programs targeting Multiple Sclerosis, Primary Progressive. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple Sclerosis, Primary ProgressiveActive, not recruiting

Multiple Sclerosis, Primary ProgressivePhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Multiple Sclerosis, Primary Progressive

#DrugCompanyPhaseTrials

Ocrevus

Roche

Phase 3

1 2

Fenebrutinib

Roche

Phase 3

1 3

Placebo matched to ocrelizumab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Multiple Sclerosis, Primary Progressive

NCT04544449

Clinical

Trials by Indication[1]

Multiple Sclerosis, Primary Progressive1 trial

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04544449·985 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo matched to ocrelizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo matched to ocrelizumab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody
Highest Phase: Phase 3[1]
Company: Roche

Placebo matched to ocrelizumab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Multiple Sclerosis, Primary Progressive1 trial

References

Drug Info

Quick Facts

Related News